All news from Anaesthesiology

Tendon, Ligament Damage Studied USing Bioinspired Imaging Technique

Tommy John surgery, or reconstruction of the ulnar collateral ligament (UCL) in the elbow, has been dubbed an epidemic among Major League Baseball pitchers. A mechanical engineer at Washington University in St. Louis plans to develop a bioinspired imaging technique to study how damage accumulates in the UCL during loading, or the stress of activating the ligament. This could provide insight into what is progressively happening to these soft tissues when pitchers throw fastballs dozens of times during a game.

Tecentriq in Lung Cancer, New Hope

Swiss drugmaker Roche's hopes of having the first immunotherapy cocktail to be approved as an initial treatment for an aggressive form of lung cancer remained intact after a trial showed positive survival data.

Exosomes In The Inner Ear Used As Biomarker

Researchers show the presence of exosomes in the inner ear and to characterize the changes in their protein content in response to ototoxic medications. Exosomes are nanovesicles involved in intercellular communications. They are released by a variety of cell types; however, their presence in the inner ear has not been described in the literature.

The study is to determine if exosomes are present in the inner ear and, if present, characterize the changes in their protein content in response to ototoxic stress. In this laboratory investigation, inner ear explants of 5-day-old Wistar rats were cultured and treated with either cisplatin or gentamicin. Hair cell damage was assessed by confocal microscopy. Exosomes were isolated using ExoQuick, serial centrifugation, and mini-column methods.

Role of PARP Inhibitor in NSCLC

In a randomized, Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, adding the PARP inhibitor veliparib to a standard chemotherapy agent improved overall response rates (ORR) in patients with small cell lung cancer (SCLC).

Researchers also identified a select group of patients—those whose tumors expressed SLFN11— who also saw a progression-free survival (PFS) and overall survival (OS) benefit, suggesting a promising biomarker for the PARP-inhibitor sensitivity in SCLC.